Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWN323 +/- Spartalizumab in Advanced Solid Tumors and Lymphomas
NCT02740270Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2016
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of gwn323 in solid tumor and lymphoma (2 arms), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities (DLTs) - Single Agent at 21 days and Incidence of Dose Limiting Toxicities (DLTs) - Combination Agents at 42 days. Started Jul 2016; status: completed.
02
Drugs
gwn323
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02740270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02740270.